TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for April 7, 2025, at 9:30 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com. The replay will remain available for 90 days following the event.

News Market Reaction – TCRX

+2.22%

+2.22% Session move

In the trading session that priced this news, TCRX gained 2.22%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24^th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When is TScan Therapeutics (TCRX) presenting at the Needham Healthcare Conference 2025?

TScan Therapeutics will present on April 7, 2025, at 9:30 a.m. Eastern Time during a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch TScan Therapeutics' (TCRX) Needham Conference presentation?

Investors can watch the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com.

How long will TScan Therapeutics' (TCRX) Needham Conference presentation be available for replay?

The webcast replay will be available for 90 days following the event on the company's website.

What type of therapies is TScan Therapeutics (TCRX) developing?

TScan Therapeutics is developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment.